The Hidden Challenge: Mutations Unique to Indian Tumors

India is witnessing a surge in cancer incidence, but a less‑discussed reality is that many Indian tumours harbour genetic mutations that differ from those most common in Western populations. Most oncology drugs are designed and tested on cohorts dominated by European and North‑American genetics, leaving a therapeutic gap for Indian patients whose cancers carry region‑specific driver mutations.

Why Imported Drugs Miss the Mark

• Genomic Diversity: Studies from the Indian Genome Variation Consortium reveal that South Asian genomes have distinct single‑nucleotide polymorphisms (SNPs) and copy‑number variations.
• Clinical Trial Bias: The majority of Phase III trials enroll patients from the US, Europe, or East Asia, rarely representing the Indian demographic.
• Pharmacogenomics: Enzyme activity (e.g., CYP450 variants) that metabolises chemotherapy can vary, affecting drug efficacy and toxicity.

A Professor’s Solution: Tailoring Cancer Care to Indian Genetics

Dr. Ananya Singh, a molecular oncologist at the National Institute of Cancer Research (NICR), has spearheaded a project that maps the mutational landscape of Indian cancers and proposes a locally‑adapted therapeutic roadmap.

The Research Blueprint

1. Large‑Scale Sequencing: Over 2,000 tumour samples across breast, lung, colorectal, and head‑and‑neck cancers were sequenced using next‑generation platforms.
2. Mutation Atlas Creation: The team identified 15 recurrent mutations that are over‑represented in Indian cohorts but are rare elsewhere, such as the FGFR2‑E587K variant in gastric cancer.
3. Drug Repurposing Pipeline: By cross‑referencing these mutations with existing drug databases, the researchers pinpointed off‑label uses of affordable generics and highlighted gaps where no approved drug exists.
4. In‑House Validation: Using patient‑derived organoids, Dr. Singh’s lab tested candidate compounds, achieving a 30‑45 % improvement in cell‑kill rates compared to standard regimens.

Key Findings

• 30 % of Indian lung‑cancer patients possess EGFR exon‑20 insertions that are poorly targeted by first‑generation EGFR inhibitors.
• 15 % of breast‑cancer cases show a novel PIK3CA‑H1047R co‑mutation that confers resistance to standard HER2‑targeted therapy.
• A subset of colorectal cancers harbours KRAS‑G12D mutations that respond to emerging KRAS inhibitors not yet approved in India.

Implications for Policy and Practice

• Regulatory Fast‑Track: The Indian drug regulator (CDSCO) could create a priority review pathway for drugs targeting these identified mutations.
• Public‑Private Partnerships: Collaboration between Indian biotech firms and global pharma can accelerate the development of mutation‑specific trials within the country.
• Cost‑Effective Precision: Leveraging generic drugs that match the mutation profile can reduce out‑of‑pocket expenses for patients, addressing both efficacy and affordability.

Takeaway for the Oncology Community

• Data‑Driven Therapy: Incorporating region‑specific genomic data into treatment algorithms can markedly improve response rates.
• Education & Training: Oncologists need updated guidelines that reflect these Indian‑specific mutational insights.
• Patient Advocacy: Awareness campaigns should highlight the importance of molecular testing, especially for cancers with known regional mutation patterns.

Looking Ahead

Dr. Singh’s work is a clarion call for a home‑grown precision oncology ecosystem. By aligning drug development with the genetic reality of Indian cancers, the nation can move from reliance on imported therapeutics to a model where science, affordability, and local relevance converge.

---

For clinicians seeking to integrate these findings, the full dataset and recommended drug‑matching matrix are available on the NICR open‑access portal.

---

Original Reporting & Source: India Today Top Stories